MRD conversion and PD status according to patients’ genetic profile status at baseline (VenR arm)
| . | . | IGHV . | GC (≥3 CNA) . | del(17p) . | |||
|---|---|---|---|---|---|---|---|
| MRD status . | ITT N = 194 . | Unmut n = 123* . | Mut n = 53* . | GC n = 48* . | No GC n = 94* . | Present n = 17* . | Absent n = 125* . |
| uMRD at EOT | 83 (42.8%) | 56 (45.5%) | 23 (43.4%) | 18 (37.5%) | 40 (42.5%) | 4 (23.5%) | 54 (43.2%) |
| Sustained uMRD | 32 (16.5%) | 20 (35.7%) | 10 (43.5%) | 5 (27.8%) | 16 (40.0%) | 0 (0%) | 21 (38.9%) |
| Conversion to MRD (no PD) | 28 (14.4%) | 15 (26.8%) | 12 (52.2%) | 5 (27.8%) | 16 (40.0%) | 0 (0%) | 21 (38.9%) |
| Conversion with subsequent PD | 19 (9.8%) | 21 (37.5%) | 1 (4.3%) | 8 (44.4%) | 8 (20.0%) | 4 (100%) | 12 (22.2%) |
| . | . | IGHV . | GC (≥3 CNA) . | del(17p) . | |||
|---|---|---|---|---|---|---|---|
| MRD status . | ITT N = 194 . | Unmut n = 123* . | Mut n = 53* . | GC n = 48* . | No GC n = 94* . | Present n = 17* . | Absent n = 125* . |
| uMRD at EOT | 83 (42.8%) | 56 (45.5%) | 23 (43.4%) | 18 (37.5%) | 40 (42.5%) | 4 (23.5%) | 54 (43.2%) |
| Sustained uMRD | 32 (16.5%) | 20 (35.7%) | 10 (43.5%) | 5 (27.8%) | 16 (40.0%) | 0 (0%) | 21 (38.9%) |
| Conversion to MRD (no PD) | 28 (14.4%) | 15 (26.8%) | 12 (52.2%) | 5 (27.8%) | 16 (40.0%) | 0 (0%) | 21 (38.9%) |
| Conversion with subsequent PD | 19 (9.8%) | 21 (37.5%) | 1 (4.3%) | 8 (44.4%) | 8 (20.0%) | 4 (100%) | 12 (22.2%) |
ITT, intention-to-treat population.
Biomarker evaluable population.